FARYDAK
Total Payments
$25.0M
Transactions
1,346
Doctors
784
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,601 | 1 | 0 |
| 2023 | $20,803 | 1 | 0 |
| 2021 | $168,360 | 513 | 334 |
| 2020 | $721,593 | 14 | 3 |
| 2019 | $8.3M | 625 | 443 |
| 2018 | $7.3M | 56 | 17 |
| 2017 | $8.5M | 136 | 57 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24.6M | 146 | 98.5% |
| Consulting Fee | $294,774 | 111 | 1.2% |
| Honoraria | $51,740 | 34 | 0.2% |
| Food and Beverage | $26,696 | 991 | 0.1% |
| Travel and Lodging | $8,496 | 11 | 0.0% |
| Education | $649.78 | 53 | 0.0% |
Payments by Type
Research
$24.6M
146 transactions
General
$382,356
1,200 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EVALUATION OF PANOBINOSTAT LBH589 AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION | Novartis Pharmaceuticals Corporation | $5.0M | 0 |
| PHASE I TRIAL OF PANOBINOSTAT IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA | Novartis Pharmaceuticals Corporation | $4.2M | 0 |
| PANOBINOSTAT WITH CARFILZOMIB AND DEXAMETHASONE FOR RELAPSED REFRACTORY MULTIPLE MYELOMA CORRELATION WITH IN VITRO CHEMOSENSITIVITY TESTING | Novartis Pharmaceuticals Corporation | $4.1M | 0 |
| PANOBINOSTAT AND OR CARFILZOMIB COMBINED WITH HIGH DOSE GEMCITABINE AND OR BUSULFAN AND OR MELPHALAN WITH AUTOLOGOUS STEM CELL TRANSPLANT FOR PATIENTS WITH REFRACTORY AND OR RELAPSED MYELOMA | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| PHASE II TRIAL OF LBH589 PANOBINOSTAT IN RELAPSED OR RELAPSED AND REFRACTORY WALDENSTROMS MACROGLOBULINEMIA | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A PHASE I AND OR B OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF ORAL PANOBINOSTAT LBH589 ADMINISTERED WITH 5 AZACITIDINE VIDAZA IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES MDS CHRONIC MYELOMONOCYTIC LEUKEMIA CMML OR ACUTE MYELOID LEUKEMIA AML | Novartis Pharmaceuticals Corporation | $931,107 | 0 |
| A MULTICENTER RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF THREE DIFFERENT REGIMENS OF ORAL PANOBINOSTAT IN COMBINATION WITH SUBCUTANEOUS BORTEZOMIB AND ORAL DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED REFRACTORY MULTIPLE MYELOMA WHO HAVE BEEN PREVIOUSLY EXPOSED TO IMMUNOMODULATORY AGENTS | Novartis Pharmaceuticals Corporation | $860,374 | 0 |
| A PHASE II STUDY OF THE HISTONE DEACETYLASE HDAC INHIBITOR LBH589 PANOBINOSTAT IN PATIENTS WITH RELAPSED OR REFRACTORY NON HODGKIN LYMPHOMA | Novartis Pharmaceuticals Corporation | $707,374 | 0 |
| PHASE I AND OR II STUDY OF PANOBINOSTAT AND CARFILZOMIB IN PATIENTS WITH RELAPSED AND OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $696,667 | 0 |
| A MULTICENTER RANDOMIZED OPEN LABEL PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF THREE DIFFERENT REGIMENS OF ORAL PANOBINOSTAT IN COMBINATION WITH SUBCUTANEOUS BORTEZOMIB AND ORAL DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED REFRACTORY MULTI | Novartis Pharmaceuticals Corporation | $668,713 | 0 |
| A PHASE 1 STUDY OF PANOBINOSTAT IN COMBINATION WITH MLN9708 IXAZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $656,667 | 0 |
| OPEN LABEL STUDY OF PANOBINOSTAT IN COMBINATION WITH LENALIDOMIDE BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $577,215 | 0 |
| A PHASE I AND OR II STUDY OF THE HISTONE DEACETYLASE HDAC INHIBITOR LBH589 PANOBINOSTAT IN COMBINATION WITH MTOR INHIBITOR RAD001 EVEROLIMUS IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA OR LYMPHOMA | Novartis Pharmaceuticals Corporation | $421,198 | 0 |
| PHASE I AND OR II STUDY OF COMBINATION ORAL JAK2 TYROSINE KINASE INHIBITOR JAK2 TKI AND HISTONE DEACETYLASE INHIBITOR HDACI THERAPY IN PATIENTS WITH MYELOFIBROSIS | Novartis Pharmaceuticals Corporation | $420,454 | 0 |
| TRIAL EVALUATING THE EFFICACY AND SAFETY OF THE COMBINATION OF PANOBINOSTAT PLUS RVD IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA | Novartis Pharmaceuticals Corporation | $361,587 | 0 |
| PHASE I AND OR II STUDY OF THE EFFICACY AND SAFETY OF THE COMBINATION OF PANOBINOSTAT AND CARFILZOMIB IN PATIENTS WITH RELAPSED AND OR REFRACTORY MYELOMA | Novartis Pharmaceuticals Corporation | $260,996 | 0 |
| CLINICAL ROLE OF HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT LBH589B FOR GRAFT VERSUS HOST DISEASE GVHD PREVENTION | Novartis Pharmaceuticals Corporation | $250,293 | 0 |
| RANDOMIZED PHASE II TRIAL EVALUATING THE EFFICACY AND SAFETY OF RVD PLUS MINUS PANOBINOSTAT IN TRANSPLANT ELIGIBLE NDMM | Novartis Pharmaceuticals Corporation | $198,599 | 0 |
| A PHASE I STUDY OF ESCALATING DOSES OF PANOBINOSTAT LBH 589 WITH IPILIMUMAB IN PATIENTS WITH STAGE IV MELANOMA | Novartis Pharmaceuticals Corporation | $183,684 | 0 |
| PHASE I AND OR II STUDY OF LBH589 AND BEVACIZUMAB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA | Novartis Pharmaceuticals Corporation | $183,334 | 0 |
Top Doctors Receiving Payments for FARYDAK — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Rock Hill, SC | $2,719 | 3 |
| , M.D | Hematology & Oncology | Tampa, FL | $2,571 | 3 |
| , MDSM | Medical Oncology | New York, NY | $2,323 | 2 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $2,000 | 1 |
| , M.D | Internal Medicine | Atlanta, GA | $2,000 | 1 |
| , MD | Hematology & Oncology | Little Rock, AR | $2,000 | 1 |
| , D.O | Hematology & Oncology | Myrtle Beach, SC | $1,945 | 4 |
| , M.D | Hematology & Oncology | Lancaster, SC | $1,734 | 4 |
| , NP-C | Family | Newark, DE | $1,700 | 2 |
| , MD | Medical Oncology | Saint Louis, MO | $1,667 | 2 |
| , MD | Medical Oncology | New York, NY | $1,602 | 2 |
| , MD | Medical Oncology | Saint Louis, MO | $1,566 | 2 |
| , M.D | Medical Oncology | Houston, TX | $1,525 | 2 |
| , MD | Hematology & Oncology | Corona, CA | $1,515 | 2 |
| , M.D | Medical Oncology | Cleveland, OH | $1,500 | 1 |
| , MD | Internal Medicine | Philadelphia, PA | $1,500 | 1 |
| , MD | Internal Medicine | Seattle, WA | $1,500 | 1 |
| , MD | Anesthesiology | Mountain View, CA | $1,375 | 1 |
| , M.D | Hematology & Oncology | Chicago, IL | $1,318 | 3 |
| , M.D | Hematology & Oncology | Clermont, FL | $1,237 | 4 |
| , M.D | Hematology & Oncology | Gettysburg, PA | $1,218 | 2 |
| , MD | Hematology & Oncology | Troy, MI | $1,200 | 1 |
| , MD | Hematology & Oncology | Marietta, GA | $1,200 | 1 |
| , M.D | Medical Oncology | Tinley Park, IL | $1,200 | 1 |
| , MD FACP | Hematology & Oncology | Utica, NY | $1,200 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $24.6M
- Secura Bio, Inc. $386,623
- NOVARTIS PHARMACEUTICALS CORPORATION $19,883
Product Information
- Type Drug
- Total Payments $25.0M
- Total Doctors 784
- Transactions 1,346
About FARYDAK
FARYDAK is a drug associated with $25.0M in payments to 784 healthcare providers, recorded across 1,346 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $1,601 was paid across 1 transactions to 0 doctors.
The most common payment nature for FARYDAK is "Unspecified" ($24.6M, 98.5% of total).
FARYDAK is associated with 20 research studies, including "EVALUATION OF PANOBINOSTAT LBH589 AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION" ($5.0M).